Edition:
United States

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

3,650.33GBp
7:27am EDT
Change (% chg)

-22.17 (-0.60%)
Prev Close
3,672.50
Open
3,665.00
Day's High
3,682.50
Day's Low
3,639.50
Volume
497,713
Avg. Vol
2,837,288
52-wk High
5,186.00
52-wk Low
3,603.50

Chart for

About

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas... (more)

Overall

Beta: 1.52
Market Cap(Mil.): £33,344.78
Shares Outstanding(Mil.): 908.51
Dividend: 3.85
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.57 16.30
EPS (TTM): -- -- --
ROI: -- 14.87 11.19
ROE: -- 16.12 15.02

Lonza buys U.S. clinical manufacturing site from Shire

ZURICH Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.

Oct 03 2017

Lonza buys U.S. clinical manufacturing site from Shire

ZURICH, Oct 3 Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.

Oct 03 2017

Shire sues Allergan in U.S. over dry eye drug

Allergan Plc was sued on Monday by Shire Plc for allegedly scheming to block doctors from prescribing its new treatment for dry eye disease.

Oct 02 2017

Shire sues Allergan in U.S. over dry eye drug

Allergan Plc was sued on Monday by Shire Plc for allegedly scheming to block doctors from prescribing its new treatment for dry eye disease.

Oct 02 2017

Shire sues Allergan in U.S. over dry eye drug

Oct 2 Allergan Plc was sued on Monday by Shire Plc for allegedly scheming to block doctors from prescribing its new treatment for dry eye disease.

Oct 02 2017

Shire, Shionogi's ADHD drug for adults clears late-stage trial in Japan

TOKYO Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.

Sep 20 2017

Shire, Shionogi's ADHD drug for adults clears late-stage trial in Japan

TOKYO, Sept 20 Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.

Sep 20 2017

BRIEF-Shire and Shionogi announce positive topline results for Intuniv ​

* ‍SHIRE AND SHIONOGI ANNOUNCE POSITIVE TOPLINE RESULTS FOR INTUNIV EVALUATED IN PHASE 3 CLINICAL TRIAL IN ADULTS WITH ADHD​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Sep 20 2017

BRIEF-Shire receives FDA fast track designation for SHP607

* SHIRE RECEIVES FDA FAST TRACK DESIGNATION FOR SHP607 FOR THE PREVENTION OF CHRONIC LUNG DISEASE IN EXTREMELY PREMATURE INFANTS

Sep 12 2017

BRIEF-Shire announces collaboration with Microhealth to address needs of hemophilia A and B patients with inhibitors

* Shire announces collaboration with Microhealth to address unique needs of hemophilia A and B patients with inhibitors Source text for Eikon: Further company coverage:

Aug 25 2017

Earnings vs. Estimates